Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Deep Venous Thrombosis Cardiovascular Diseases Embolism and Thrombosis Thrombosis Vascular Diseases Venous Thrombosis

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Cairo University

Cairo, 11511, Egypt

About this study

This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BARIATRIC PATIENTS

Exclusion criteria

BLEEDING TENDENCY

Treatment and study plan

Direct Oral Anticoagulant.

Drug

Direct Oral Anticoagulant AFTER BARIATRIC SURGERY

Other names: RIVROXABAN

Low Molecular Weight Heparine

Drug

Low molecular weight heparin after bariatric surgery

Other names: Enoxaparine

Primary outcomes

VENOUS THROMBOEMBOLISM

Time frame: 1 year

DVT after bariatric surgery

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Apr 6, 2025
Registry last updated: Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting